Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:IPHA NASDAQ:JSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$5.32+9.0%$3.43$1.78▼$8.56$102.40M0.98747,650 shs390,308 shsIPHAInnate Pharma$2.04+1.2%$2.05$1.29▼$3.51$185.24M0.0420,063 shs4,230 shsJSPRJasper Therapeutics$2.49+3.8%$2.66$2.21▼$26.05$39.01M2.79463,019 shs439,068 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+9.02%+0.95%+53.31%+109.45%-29.26%IPHAInnate Pharma+2.26%+1.25%-0.25%+16.74%-3.33%JSPRJasper Therapeutics+3.75%+2.89%-3.86%-29.06%-83.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$5.32+9.0%$3.43$1.78▼$8.56$102.40M0.98747,650 shs390,308 shsIPHAInnate Pharma$2.04+1.2%$2.05$1.29▼$3.51$185.24M0.0420,063 shs4,230 shsJSPRJasper Therapeutics$2.49+3.8%$2.66$2.21▼$26.05$39.01M2.79463,019 shs439,068 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+9.02%+0.95%+53.31%+109.45%-29.26%IPHAInnate Pharma+2.26%+1.25%-0.25%+16.74%-3.33%JSPRJasper Therapeutics+3.75%+2.89%-3.86%-29.06%-83.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.40Hold$19.75271.24% UpsideIPHAInnate Pharma 2.00Hold$6.50219.41% UpsideJSPRJasper Therapeutics 2.45Hold$25.63929.12% UpsideCurrent Analyst Ratings BreakdownLatest JSPR, ADVM, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ADVMAdverum BiotechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IPHAInnate PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025JSPRJasper TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ADVMAdverum BiotechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell ➝ Sell (D-)9/27/2025IPHAInnate PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025JSPRJasper TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/23/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.009/22/2025JSPRJasper TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $14.009/22/2025JSPRJasper TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$12.00 ➝ $6.009/22/2025JSPRJasper TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $7.009/18/2025IPHAInnate PharmaLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M111.61N/AN/A$3.40 per share1.56IPHAInnate Pharma$21.77M8.62N/AN/A$0.11 per share18.50JSPRJasper TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)IPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/AN/AJSPRJasper Therapeutics-$71.27M-$6.01N/AN/AN/AN/A-172.28%-128.34%11/6/2025 (Estimated)Latest JSPR, ADVM, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025JSPRJasper Therapeutics-$1.01N/AN/AN/AN/AN/A11/3/2025Q3 2025ADVMAdverum Biotechnologies-$1.80N/AN/AN/AN/AN/A8/13/2025Q2 2025JSPRJasper Therapeutics-$1.20-$1.74-$0.54-$1.74N/AN/A8/12/2025Q2 2025ADVMAdverum Biotechnologies-$2.24-$2.34-$0.10-$2.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A1.541.54IPHAInnate Pharma3.522.21N/AJSPRJasper TherapeuticsN/A2.102.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%IPHAInnate Pharma0.16%JSPRJasper Therapeutics79.85%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%IPHAInnate Pharma31.89%JSPRJasper Therapeutics4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.98 million19.73 millionOptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableJSPRJasper Therapeutics2016.25 million15.51 millionOptionableJSPR, ADVM, and IPHA HeadlinesRecent News About These CompaniesPortnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. InvestorsOctober 9 at 3:14 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPROctober 8 at 4:30 PM | prnewswire.comJSPR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of JasperOctober 8 at 10:10 AM | globenewswire.comSecurities Fraud Investigation Into Jasper Therapeutics, Inc. (JSPR) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities ...October 7 at 12:15 AM | theglobeandmail.comJSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud LawsuitOctober 7 at 5:07 PM | prnewswire.comJasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 7 at 4:00 PM | prnewswire.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPROctober 7 at 3:00 PM | globenewswire.comJasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPROctober 7 at 8:04 AM | prnewswire.comRobbins LLP Reminds Jasper Therapeutics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against JSPROctober 6, 2025 | prnewswire.comJSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitOctober 6, 2025 | globenewswire.comJSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of JasperOctober 5, 2025 | globenewswire.comROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPROctober 5, 2025 | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. InvestorsOctober 3, 2025 | globenewswire.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of JasperOctober 3, 2025 | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPROctober 3, 2025 | prnewswire.comJasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 2, 2025 | prnewswire.comJSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud LawsuitOctober 2, 2025 | prnewswire.comROSEN, A RANKED AND LEADING LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – JSPROctober 1, 2025 | globenewswire.comJasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 1, 2025 | prnewswire.comJasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09September 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJSPR, ADVM, and IPHA Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$5.32 +0.44 (+9.02%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$5.31 -0.01 (-0.19%) As of 05:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Innate Pharma NASDAQ:IPHA$2.04 +0.03 (+1.24%) Closing price 10/9/2025 03:56 PM EasternExtended Trading$2.08 +0.05 (+2.41%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Jasper Therapeutics NASDAQ:JSPR$2.49 +0.09 (+3.75%) Closing price 10/9/2025 04:00 PM EasternExtended Trading$2.47 -0.02 (-0.80%) As of 10/9/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
